This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.
Histologically or cytologically confirmed diagnosis of non- oncogene addicted advanced, locally advanced (not suitable for definitive chemoradiation therapy) or metastatic non-small-cell lung cancer (NSCLC)
Any patient candidate for first line chemo-immunotherapy irrespective of PD-L1 levels
HLA-A2 positive
ECOG PS 0-1
Patients not candidate for chemo-immunotherapy
HLA-A2 negative
Symptomatic or not previously treated and not stable brain metastases. Brain metastases are allowed if asymptomatic or pretreated
Tumor tissue not available (archive or collected before trial inclusion)